Note: [01 Mar 2017] – The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative.

FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS – PARTICIPATION FEE

MANAGEMENT CERTIFICATION

I, <u>Robert Lelovic</u> , an officer of Form 13-501F1 (the Form) being submicertify that to my knowledge, having exit the Form is complete and accurate.	itted hereunder to the Alber	ta Securi	ities Com	mission and
"Robert Lelovic"		March 30	2021	
Name: Robert Lelovic Title: CFO	Date:			
Reporting Issuer Name:	Rise Life Science Corp.			
End date of previous financial year:	November 30, 2020			
Type of Reporting Issuer:	[×] Class 1 reporting issuer	[] C issuer	Class 3B r	eporting
Highest Trading Marketplace:	TSXV			
Market value of listed or quoted equit	ty securities:			
Equity Symbol		RLSC		-
1st Specified Trading Period (dd/mm/	yy)01	L/12/19	to	28/02/20
Closing price of the security in the class last trading day of the specified trading such security was listed or quoted on the marketplace	period in which	\$ (i)		0.0050

Number of securities in the class or series of such security outstanding at the end of the last trading day the specified trading period	of	(ii)		60,310,352
Market value of class or series	(i) x (ii)	\$(A)		301,551.7600
2nd Specified Trading Period (dd/mm/yy)		01/03/20	to	31/05/20
Closing price of the security in the class or series on t last trading day of the specified trading period in whi such security was listed or quoted on the highest trad marketplace	ch	\$		0.0200
Number of securities in the class or series of such security outstanding at the end of the last trading day the specified trading period	of	(iv)		60,310,352
Market value of class or series	(iii) x (iv	(B)		1,206,207.0400
3rd Specified Trading Period (dd/mm/yy)		01/06/20	to	31/08/20
Closing price of the security in the class or series on t last trading day of the specified trading period in whi such security was listed or quoted on the highest trad marketplace	ch	\$(v)		0.0200
Number of securities in the class or series of such security outstanding at the end of the last trading day the specified trading period	of	(vi)		60,310,352
Market value of class or series	(v) x (vi))		1,206,207.0400

4th Specified Trading Period (dd/mm/yy)	01/	/09/20	_to _	30/11/20
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest tradin marketplace	l	\$(vii)		0.0200
Number of securities in the class or series of such security outstanding at the end of the last trading day o the specified trading period	f	(viii)		60,310,352
Market value of class or series	(vii) x (viii)	\$ (D)		1,206,207.0400
5th Specified Trading Period (dd/mm/yy)			_ to	
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest tradin marketplace	l	\$ (ix)		
Number of securities in the class or series of such security outstanding at the end of the last trading day o the specified trading period	f	(x)		
Market value of class or series	(ix) x (x)	\$(E)		
Average Market Value of Class or Series (Calculate the simple average of the market value of the class or series of security for each applicable specified trading period (i.e. A through E above))		\$ (1)		980,043.2200

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

Fair value of outstanding debt securities:

(Provide details of how value was determined)		\$(2)	
Capitalization for the previous financial year	(1) + (2)	\$	980,043.2200
Participation Fee		\$	400.0000
Late Fee, if applicable		\$	
Total Fee Payable (Participation Fee plus Late Fee)		\$	400.0000